AU2011323197B2 - Control and characterization of psychotic states - Google Patents
Control and characterization of psychotic states Download PDFInfo
- Publication number
- AU2011323197B2 AU2011323197B2 AU2011323197A AU2011323197A AU2011323197B2 AU 2011323197 B2 AU2011323197 B2 AU 2011323197B2 AU 2011323197 A AU2011323197 A AU 2011323197A AU 2011323197 A AU2011323197 A AU 2011323197A AU 2011323197 B2 AU2011323197 B2 AU 2011323197B2
- Authority
- AU
- Australia
- Prior art keywords
- light
- depolarization
- layer
- neurons
- opsin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000028017 Psychotic disease Diseases 0.000 title claims abstract description 106
- 238000012512 characterization method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 79
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 230000001939 inductive effect Effects 0.000 claims abstract description 16
- 230000028161 membrane depolarization Effects 0.000 claims description 126
- 230000000694 effects Effects 0.000 claims description 118
- 210000001176 projection neuron Anatomy 0.000 claims description 114
- 210000002569 neuron Anatomy 0.000 claims description 105
- 230000001419 dependent effect Effects 0.000 claims description 78
- 210000002442 prefrontal cortex Anatomy 0.000 claims description 67
- 230000004913 activation Effects 0.000 claims description 45
- 210000000170 cell membrane Anatomy 0.000 claims description 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 230000001413 cellular effect Effects 0.000 claims description 25
- 238000005259 measurement Methods 0.000 claims description 25
- 239000012528 membrane Substances 0.000 claims description 22
- 239000000556 agonist Substances 0.000 claims description 16
- 230000036755 cellular response Effects 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 12
- 210000001787 dendrite Anatomy 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000003542 behavioural effect Effects 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 7
- 108050001704 Opsin Proteins 0.000 abstract description 99
- 102000010175 Opsin Human genes 0.000 abstract description 98
- 241001465754 Metazoa Species 0.000 abstract description 37
- 238000012216 screening Methods 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 141
- FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 83
- 229950001037 quinpirole Drugs 0.000 description 82
- 230000004044 response Effects 0.000 description 73
- 230000000638 stimulation Effects 0.000 description 63
- 229940079593 drug Drugs 0.000 description 55
- 239000003814 drug Substances 0.000 description 55
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 53
- 230000003287 optical effect Effects 0.000 description 52
- 201000000980 schizophrenia Diseases 0.000 description 49
- 230000006399 behavior Effects 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 43
- 108091006146 Channels Proteins 0.000 description 42
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 40
- 238000012421 spiking Methods 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 32
- 239000011575 calcium Substances 0.000 description 30
- 101150049660 DRD2 gene Proteins 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 28
- 230000002999 depolarising effect Effects 0.000 description 28
- 238000011282 treatment Methods 0.000 description 28
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 229960001597 nifedipine Drugs 0.000 description 23
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 23
- 230000002360 prefrontal effect Effects 0.000 description 23
- 229960004940 sulpiride Drugs 0.000 description 23
- 229960003878 haloperidol Drugs 0.000 description 20
- 235000021251 pulses Nutrition 0.000 description 20
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 230000001594 aberrant effect Effects 0.000 description 18
- 239000005557 antagonist Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 108091005462 Cation channels Proteins 0.000 description 15
- 208000020016 psychiatric disease Diseases 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 238000011830 transgenic mouse model Methods 0.000 description 14
- 102000034573 Channels Human genes 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000001537 neural effect Effects 0.000 description 13
- 230000002035 prolonged effect Effects 0.000 description 13
- 241000699660 Mus musculus Species 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 230000005284 excitation Effects 0.000 description 12
- 230000002102 hyperpolarization Effects 0.000 description 12
- 230000002385 psychotomimetic effect Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 230000004064 dysfunction Effects 0.000 description 10
- 230000036982 action potential Effects 0.000 description 9
- 206010007776 catatonia Diseases 0.000 description 9
- 210000003061 neural cell Anatomy 0.000 description 9
- 238000010304 firing Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000002085 persistent effect Effects 0.000 description 8
- 229950010883 phencyclidine Drugs 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010037249 Psychotic behaviour Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000013607 AAV vector Substances 0.000 description 5
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000004310 Ion Channels Human genes 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 5
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 5
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 5
- 241000195614 Volvox carteri Species 0.000 description 5
- 239000000164 antipsychotic agent Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000000763 evoking effect Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002336 repolarization Effects 0.000 description 5
- 230000011273 social behavior Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 241000195585 Chlamydomonas Species 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 229940005529 antipsychotics Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 239000013307 optical fiber Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 241000125945 Protoparvovirus Species 0.000 description 3
- 101150052863 THY1 gene Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000004205 output neuron Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108010035848 Channelrhodopsins Proteins 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 229940122282 L-type calcium channel antagonist Drugs 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 101000903581 Natronomonas pharaonis Halorhodopsin Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000004176 azorubin Substances 0.000 description 2
- 239000001654 beetroot red Substances 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000004886 head movement Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000478 neocortex Anatomy 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000011422 pharmacological therapy Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002763 pyramidal cell Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000009424 underpinning Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 102000014814 CACNA1C Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000195633 Dunaliella salina Species 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000009855 Inwardly Rectifying Potassium Channels Human genes 0.000 description 1
- 108010009983 Inwardly Rectifying Potassium Channels Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010043114 Tangentiality Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000195615 Volvox Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000012018 cellular response to stimulus Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000000530 impalefection Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000004298 light response Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000009745 pathological pathway Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000003196 psychodysleptic agent Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000021670 response to stimulus Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016200948A AU2016200948A1 (en) | 2010-11-05 | 2016-02-15 | Control and characterization of psychotic states |
| AU2018208657A AU2018208657A1 (en) | 2010-11-05 | 2018-07-24 | Control and characterization of psychotic states |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41072010P | 2010-11-05 | 2010-11-05 | |
| US41072510P | 2010-11-05 | 2010-11-05 | |
| US61/410,720 | 2010-11-05 | ||
| US61/410,725 | 2010-11-05 | ||
| PCT/US2011/059383 WO2012061741A2 (en) | 2010-11-05 | 2011-11-04 | Control and characterization of psychotic states |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016200948A Division AU2016200948A1 (en) | 2010-11-05 | 2016-02-15 | Control and characterization of psychotic states |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011323197A1 AU2011323197A1 (en) | 2013-05-09 |
| AU2011323197B2 true AU2011323197B2 (en) | 2015-11-19 |
Family
ID=46025139
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011323197A Ceased AU2011323197B2 (en) | 2010-11-05 | 2011-11-04 | Control and characterization of psychotic states |
| AU2016200948A Abandoned AU2016200948A1 (en) | 2010-11-05 | 2016-02-15 | Control and characterization of psychotic states |
| AU2018208657A Abandoned AU2018208657A1 (en) | 2010-11-05 | 2018-07-24 | Control and characterization of psychotic states |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016200948A Abandoned AU2016200948A1 (en) | 2010-11-05 | 2016-02-15 | Control and characterization of psychotic states |
| AU2018208657A Abandoned AU2018208657A1 (en) | 2010-11-05 | 2018-07-24 | Control and characterization of psychotic states |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20140082758A1 (enExample) |
| EP (1) | EP2635110B1 (enExample) |
| JP (2) | JP5986575B2 (enExample) |
| CN (2) | CN106267236A (enExample) |
| AU (3) | AU2011323197B2 (enExample) |
| CA (1) | CA2816987C (enExample) |
| ES (1) | ES2682962T3 (enExample) |
| WO (1) | WO2012061741A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US10052497B2 (en) | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
| US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
| US20070053996A1 (en) | 2005-07-22 | 2007-03-08 | Boyden Edward S | Light-activated cation channel and uses thereof |
| WO2008086470A1 (en) | 2007-01-10 | 2008-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| WO2008101128A1 (en) | 2007-02-14 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
| WO2008106694A2 (en) | 2007-03-01 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
| US10035027B2 (en) | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
| US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
| SG189813A1 (en) | 2008-04-23 | 2013-05-31 | Univ Leland Stanford Junior | Systems, methods and compositions for optical stimulation of target cells |
| JP5890176B2 (ja) | 2008-05-29 | 2016-03-22 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | セカンドメッセンジャーを光制御するためのセルライン、システム、および方法 |
| EP2303405A4 (en) | 2008-06-17 | 2017-12-27 | The Board of Trustees of the Leland Stanford Junior University | Apparatus and methods for controlling cellular development |
| AU2009260029B2 (en) | 2008-06-17 | 2016-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods, systems and devices for optical stimulation of target cells using an optical transmission element |
| US9101759B2 (en) | 2008-07-08 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
| NZ602416A (en) | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
| JP5866332B2 (ja) | 2010-03-17 | 2016-02-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 感光性イオンを通過させる分子 |
| WO2012061681A1 (en) | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University. | Control and characterization of memory function |
| EP3486253A1 (en) | 2010-11-05 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
| CA2816987C (en) * | 2010-11-05 | 2018-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Control and characterization of psychotic states |
| US9992981B2 (en) | 2010-11-05 | 2018-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of reward-related behaviors |
| CN106106368A (zh) | 2010-11-05 | 2016-11-16 | 斯坦福大学托管董事会 | 光控cns功能障碍 |
| CA2817175C (en) | 2010-11-05 | 2019-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Upconversion of light using lanthanide-doped nanoparticles for use in optogenetic methods |
| CN103491770B (zh) | 2010-11-05 | 2016-06-08 | 斯坦福大学托管董事会 | 稳定阶跃函数视蛋白及其使用方法 |
| US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
| EP3524676A1 (en) | 2011-12-16 | 2019-08-14 | The Board of Trustees of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
| ES2628006T3 (es) | 2012-02-21 | 2017-08-01 | Circuit Therapeutics, Inc. | Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico |
| US10974064B2 (en) | 2013-03-15 | 2021-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of behavioral state |
| US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
| WO2014179331A2 (en) | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
| CA2921221A1 (en) | 2013-08-14 | 2015-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for controlling pain |
| EP3122761B1 (en) | 2014-03-28 | 2019-03-06 | The Board of Trustees of The Leland Stanford Junior University | Engineered light-activated anion channel proteins and methods of use thereof |
| US9279797B2 (en) | 2014-06-12 | 2016-03-08 | Axion Biosystems, Inc. | Multiwell microelectrode array with optical stimulation |
| WO2016209654A1 (en) | 2015-06-22 | 2016-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
| US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
| WO2025041032A1 (en) * | 2023-08-22 | 2025-02-27 | Friedrich Miescher Institute For Biomedical Research | Promoter for the specific expression of genes in layer 5 cells in mouse cortex |
| WO2025041033A1 (en) * | 2023-08-22 | 2025-02-27 | Friedrich Miescher Institute For Biomedical Research | Promoter for the specific expression of genes in layer 5 pyramidal tract cells in mouse cortex |
| WO2025041034A1 (en) * | 2023-08-22 | 2025-02-27 | Friedrich Miescher Institute For Biomedical Research | Promoter for the specific expression of genes in layer 5 cells in mouse cortex |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001263199B2 (en) * | 2000-05-17 | 2004-09-16 | Asterias Biotherapeutics, Inc. | Neural progenitor cell populations |
| EP1573314B1 (en) * | 2002-12-16 | 2008-07-23 | Genentech, Inc. | Transgenic mice expressing human cd20 |
| US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
| US7521590B2 (en) * | 2006-09-01 | 2009-04-21 | Korea Institute Of Science And Technology | Phospholipase C β1 (PLCβ1) knockout mice as a model system for testing schizophrenia drugs |
| NZ602416A (en) * | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
| WO2011005978A2 (en) * | 2009-07-08 | 2011-01-13 | Duke University | Methods of manipulating cell signaling |
| EP3486253A1 (en) * | 2010-11-05 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
| CN103491770B (zh) | 2010-11-05 | 2016-06-08 | 斯坦福大学托管董事会 | 稳定阶跃函数视蛋白及其使用方法 |
| CA2816987C (en) * | 2010-11-05 | 2018-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Control and characterization of psychotic states |
-
2011
- 2011-11-04 CA CA2816987A patent/CA2816987C/en not_active Expired - Fee Related
- 2011-11-04 ES ES11838895.8T patent/ES2682962T3/es active Active
- 2011-11-04 US US13/882,566 patent/US20140082758A1/en not_active Abandoned
- 2011-11-04 CN CN201610649118.6A patent/CN106267236A/zh active Pending
- 2011-11-04 EP EP11838895.8A patent/EP2635110B1/en not_active Not-in-force
- 2011-11-04 JP JP2013537878A patent/JP5986575B2/ja not_active Expired - Fee Related
- 2011-11-04 AU AU2011323197A patent/AU2011323197B2/en not_active Ceased
- 2011-11-04 WO PCT/US2011/059383 patent/WO2012061741A2/en not_active Ceased
- 2011-11-04 CN CN201180060052.2A patent/CN103339505B/zh not_active Expired - Fee Related
-
2016
- 2016-02-15 AU AU2016200948A patent/AU2016200948A1/en not_active Abandoned
- 2016-07-19 US US15/214,402 patent/US20160316732A1/en not_active Abandoned
- 2016-08-05 JP JP2016155068A patent/JP2017029148A/ja active Pending
-
2018
- 2018-07-24 AU AU2018208657A patent/AU2018208657A1/en not_active Abandoned
-
2020
- 2020-08-25 US US17/002,330 patent/US20210059230A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| ARENKIEL B.R. et al., Neuron, 2007, Vol. 54, pages 205-218 * |
| WANG H. et al., Proceedings of the National Academy of Sciences, 2007, Vol. 104, pages 8143-8148 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210059230A1 (en) | 2021-03-04 |
| JP2013544091A (ja) | 2013-12-12 |
| US20160316732A1 (en) | 2016-11-03 |
| CA2816987C (en) | 2018-09-18 |
| CN106267236A (zh) | 2017-01-04 |
| AU2011323197A1 (en) | 2013-05-09 |
| WO2012061741A3 (en) | 2013-08-08 |
| US20140082758A1 (en) | 2014-03-20 |
| CN103339505A (zh) | 2013-10-02 |
| ES2682962T3 (es) | 2018-09-24 |
| EP2635110A2 (en) | 2013-09-11 |
| WO2012061741A2 (en) | 2012-05-10 |
| AU2016200948A1 (en) | 2016-03-03 |
| CN103339505B (zh) | 2016-08-24 |
| CA2816987A1 (en) | 2012-05-10 |
| JP5986575B2 (ja) | 2016-09-06 |
| JP2017029148A (ja) | 2017-02-09 |
| EP2635110B1 (en) | 2018-05-09 |
| EP2635110A4 (en) | 2014-02-26 |
| AU2018208657A1 (en) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210059230A1 (en) | Control and Characterization of Psychotic States | |
| US10717769B2 (en) | Channelrhodopsins for optical control of cells | |
| US10307609B2 (en) | Compositions and methods for controlling pain | |
| US9636380B2 (en) | Optogenetic control of inputs to the ventral tegmental area | |
| CN103491770B (zh) | 稳定阶跃函数视蛋白及其使用方法 | |
| AU2013235517B2 (en) | Non-human animal models of depression and methods of use thereof | |
| US20190241627A1 (en) | Light-activated chimeric opsins and methods of using the same | |
| US9992981B2 (en) | Optogenetic control of reward-related behaviors | |
| Mantoan | Neuronal Signalling Studied with Light-activated Ion Channels to Target Interneurons, Entrain Hippocampal Gamma Oscillations and Suppress Epileptiform Activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |